Incidence, antimicrobial susceptibility & out of pocket expenditure of severe enteric fever in Chandigarh, north India

Madhu Gupta[1], Adarsh Bansal[1], Firoz Khan[1], Vivek Sagar[1], Vikas Suri[2], Arun Bansal[3], Vishal Guglani[4], Vidushi Mahajan[4], Sadbhavna Pandit[5], Gurinder Singh[6], Krishna Chaudhary[7] & Shankar Prinja[1]

Departments of [1]Community Medicine and School of Public Health, [2]Internal Medicine, [3]Advanced Paediatric Centre, Postgraduate Institute of Medical Education and Research, [4]Department of Paediatrics, Government Medical College and Hospital, Departments of [5]Pediatric, & [6]General Medicine, Government Multispecialty Hospital & [7]Civil Hospital, Chandigarh, India

Background & objectives: Burden estimates of enteric fever are required to make policy decisions on introducing typhoid vaccine in India. Incidence, antimicrobial susceptibility, and out-of-pocket expenditure (OOPE) of enteric fever are estimated in Chandigarh, India.

Methods: A hybrid (facility and community-based) surveillance system was set up at a secondary care hospital to enrol patients above six months of age, hospitalized with fever, from a defined catchment population from May 2018 to March 2020. Blood samples were collected and cultured using an automated system (BD BACTEC™ blood culture system). The *Salmonella Typhi* and *S. Paratyphi* isolates were characterized for antimicrobial susceptibility. OOPE was recorded after 14 and 28 days of discharge.

Results: Blood samples were collected from 97 per cent of the 1650 study participants enrolled. The incidence of enteric fever was 226.8 per 1,00,000 person-years (PY), severe typhoid fever 156.9 per 1,00,000 PY, and severe paratyphoid fever 69.9 per 1,00,000 PY. *Salmonella* was highly susceptible to ampicillin, azithromycin, and ceftriaxone (99.25%) and least susceptible to ciprofloxacin (11.3%). The OOPE due to hospitalization of individuals infected with *S. Paratyphi* [INR 8696.6 (USD 116)] was significantly higher than the individuals infected with *S. Typhi* [INR 7309 (USD 97.5), *P*=0.01], and among cases who were hospitalized for more than seven days [INR 12,251 (USD 163.3)] as compared with those with a stay of 3-7 days [INR 8038.2 (USD 107.2)] or less than three days [INR 5327.8 (USD 71), *P*<0.001].

Interpretation & conclusions: There was a high incidence of enteric fever, high OOPE, and resistance to ciprofloxacin.

Key words Enteric fever, epidemiology, incidence, OOPE, *Salmonella*, surveillance, typhoid

Enteric fever is a significant cause of morbidity and mortality across the globe, with an estimated annual burden of about 11,000,000 cases and 1,170,000 deaths[1]. India alone accounts for 82 and 75 per cent of

this incidence and mortality in South Asia[1]. Recently, an estimated incidence of 108 to 970 cases per 100,000 person-years (PY) among 15 yrs of age or older and 12 to 1622 cases per 100,000 child-years among children between six months and 14 yr of age has been reported in a hospital-based surveillance system in India[2]. With the emergence of antibiotic-resistant strains such as the H58 haplotype in the 1990s, typhoid is becoming difficult to treat[3]. The emergence of extensively drug-resistant *Salmonella Typhi* in Pakistan highlights the need for urgent control measures[4]. A study conducted in five Asian countries reported a high cost of hospitalized cases of typhoid fever in Kolkata, India (USD 129) and Jakarta (USD 432)[5].

Interventions focusing on improving water quality and sanitation, health education of the community, access to better diagnostics, effective typhoid vaccine, and treatment facilities could lead to the control of typhoid fever[6]. World Health Organization's (WHO) position paper on typhoid vaccines recommends the use of typhoid conjugate vaccines (TCV) in children over six months of age in countries with a high burden of typhoid[7]. Community-based typhoid vaccination programmes in New Delhi in 2004 and Navi Mumbai in 2018 were reportedly effective in reducing typhoid infections[8,9]. However, to introduce vaccines in the national immunization programme, there is a further need to generate evidence around geographically representative data on the burden, severity, and cost of illness, which could guide the policymakers in making rational decisions[10].

Surveillance programmes in many countries in Asia and Africa, such as Severe Typhoid Fever in Africa, Strategic Typhoid Alliance across Africa and Asia, Surveillance for Enteric Fever in Asia Program, and Surveillance for Enteric Fever in India (SEFI) with standard methodologies are established to measure the burden of enteric fever[11]. SEFI was a three-tier surveillance system established in India between 2017-2020. The first tier, estimates community-based enteric fever incidence through active surveillance at four sites[2]. The second tier, in secondary care hospitals with a defined catchment population, reported the incidence of severe enteric fever cases at six sites *via* hybrid methodology[2]. The third tier was established at eight tertiary care hospitals to examine the antimicrobial susceptibility patterns and spectrum of clinical severity in culture-confirmed enteric fever cases. In this study, we present the incidence of enteric fever, antimicrobial susceptibility patterns, and cost of illness in Chandigarh under the second-tier surveillance system.

Material & Methods

A facility-based surveillance and community-based healthcare utilization survey (HCUS) hybrid was conducted from May 2018 to March 2020[2] at Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh after obtaining approval from the Institutional Ethics Committee and Chandigarh Administration. After sharing the participant information sheet, written informed consent was obtained from the study participants/legal guardians. A written assent was obtained from the children aged seven to 18 yr.

I. Facility-Based Surveillance System:

Study area and health facility: The surveillance was set up in a secondary care, 50-bedded Civil Hospital, Chandigarh, where >75 per cent of individuals with febrile illness were admitted from the catchment area (a mix of urban and urbanized village) with a population of 1,43,000.

Study population: Individual aged six months and above from the catchment area admitted to the study hospital (emergency/medicine/paediatrics/obstetrics and gynecology ward) for more than six hours with acute febrile illness (temperature >98.4°F) qualified to be included in the study. Study participants with positive blood cultures for *Salmonella Typhi* or *Salmonella Paratyphi* (A/B/C) were considered confirmed severe typhoid or paratyphoid fever cases[2,11]. We enrolled 273 paediatric cases (< 15 yr) and 1377 adults (≥15 yr). Due to the non-availability of a paediatrician between January 2019 and March 2020 in the study hospital, 67 paediatric cases from the catchment area were enrolled in the referral hospitals.

Data collection methods and tools: The surveillance team, comprising a medical officer, public health officer, nurses, field investigators, and laboratory technicians, was trained by community and internal medicine experts. The eligible individuals, identified by screening the admission registers in casualty/wards, were approached; consent obtained, matched with the inclusion and exclusion criteria and recruited consecutively. A pretested predesigned structured interview schedule was used to collect information regarding socio-demographic profile, clinical signs and symptoms, and medical history and laboratory investigations related to the current episode of illness by face-to-face interviews. (Supplementary Material I). Hospital records/treatment

charts were used to retrieve information on the course of illness and treatment, including antibiotics administered during hospitalization. The culture-confirmed enteric fever individuals were recontacted telephonically or by visiting their homes on the 14th and 28th day of discharge to collect information regarding the course of illness after discharge using a recontact form (Supplementary Material II). Data regarding out-of-pocket expenditure (OOPE) on the cost of illness, including direct medical and non-medical, and the indirect costs per day in the hospital, days 14 and 28 of admission, was collected for culture-confirmed enteric fever cases using a pretested and predesigned questionnaire (Supplementary Material III). The detailed methodology of the cost of illness due to severe enteric fever is presented elsewhere[12].

Laboratory procedures: About 1-3 ml blood sample was obtained from the infants, 3-5 ml from study participants of age 1-15 yr, and 8-10 ml from adults (≥15 yr) to ensure the adequacy of blood volume for better sensitivity[13,14]. The blood samples were cultured in the department of Medical Microbiology, PGIMER, Chandigarh, using an automated system (BD BACTEC[TM] FX40 blood culture system)[15]. *S. Typhi* and *S. Paratyphi* isolates were characterized for antimicrobial susceptibility patterns using the disc diffusion method[16]. The isolates were stored in nutrient-deep agar in the Department of Microbiology, PGIMER, at -80°C before shipping to Central Laboratory, Christian Medical College (CMC), Vellore, for further genomic characterization. The susceptibility patterns of *Salmonella* were assessed against ampicillin, azithromycin, ceftriaxone, chloramphenicol, ciprofloxacin, cotrimoxazole, and nalidixic acid. These drugs were used routinelyduring antimicrobial susceptibility testing per the standard operating procedures. Nalidixic acid was not used to treat the study participants because of its reported resistance against Salmonella[17,18].

Data quality assurance: The study coordinator (AB) visited the study sites thrice a week and crosschecked all the forms with the source documents. The principal investigator (MG) supervised weekly and crosschecked 10 per cent of the forms filled. The external monitoring team from CMC, Vellore, supervised six monthly and randomly crosschecked 10 per cent of the forms. The internal and external team maintained quality control of the blood sample collection, storage, and transportation to the study laboratory as per standard operating procedures.

II. Healthcare Utilization Survey (HCUS): HCUS was conducted in 2019 by an independent agency recruited by the CMC, Vellore, to estimate the proportion of all febrile hospitalizations from the catchment population in the study hospital[19]. This was achieved through household surveys in the catchment area, in which the details on household socio-economic status, individual demographics, illness episodes based on a 2 wk recall, hospitalization events based on a six month recall, and deaths that occurred over the past year were collected.

Data analysis: Statistical analysis was done using Statistical Package for Social Sciences version 21 (SPSS Inc., IBM Corp, Chicago, Armonk, NY). The crude incidence of severe enteric fever was estimated by dividing the number of culture-confirmed typhoid and paratyphoid fevers by the catchment population (2019-2020) and adjusting for the surveillance period. Crude incidence of typhoid and paratyphoid fever was calculated per lakh person-years (population x time spent by a participant in the study). Based on the results of HCUS, the incidence of enteric fever was adjusted using a multiplier, *i.e.,* the reciprocal of the proportion of febrile illness hospitalizations from the catchment areas at the surveillance hospital (A1), compliance to the study protocol (A2), and poor sensitivity of blood culture using an adjustment based on blood volume inoculated in culture (A3)[2]. The correction for blood culture sensitivity was assumed to be 60 per cent, with an uncertainty range from 50-70 per cent[20]. The adjusted incidence was calculated as follows: Crude Incidence/A1*A2*A3. The quantitative data was analyzed using the student's *t* test, and the ordinal data was analyzed using the Mann-Whitney U Test. Multiple logistic regression analysis was done to understand the relationship between the different confounding variables and the positivity of blood cultures for enteric fever. The costing information for all the culture-confirmed enteric fever cases was presented in terms of mean expenditure and standard deviation.

Results

Of the 2652 febrile admissions in the study hospitals during the study period, 1650 (62.2%) individuals met the eligibility criteria. As blood samples were obtained from 1600 (97%) study participants, including 244 (15.25%) paediatric and 1356 (84.7%) adult samples, these were enrolled. The proportion of blood samples collected on day one of admission was 85 per cent, on day two 14 per cent, and beyond day two was one per cent. The mean days of illness at which the blood sample

Figure. Year-wise and Month-wise trend of culture-confirmed enteric fever cases at study hospitals.

was collected was 6.23. The mean blood volume was 9.36 ml for the age group >15 yr and 7.2 ml for the age group <15 yr. The most common pathogen found in the blood culture was *S. Typhi* (n=92; 5.75%), followed by *S. Paratyphi* (n=41; 2.56%), *Escherichia Coli* (n=5; 0.3%) and *Staphylococcus* (n=4; 0.25%). The seasonal trend of *S. Typhi* and *S. Paratyphi* is shown in Figure.

There was a significantly (*P* value=0.046) higher proportion of males among enteric fever cases (63.9%) as compared to non-enteric fever cases (54.9%) and the paediatric age group (22.5%) was more affected among them as compared to non-enteric fever cases (16%) (Table I). Significant risk factors of culture-confirmed enteric fever cases were being a male [Adjusted odd ratio (AOR) 1.4, 95% confidence interval (CI): 1.01, 2.1, *P*=0.046], age <15 yr (AOR 1.5, 95% CI: 0.99, 2.34, *P*=0.03) and number of days between the onset of illness and admission to the study hospital of more than three days (AOR 2.37, 95% CI: 1.22,4.6, *P*-0.01) (Table II). The clinical features of the enrolled participants are given in Supplementary Table I. More than 90 per cent of the isolates of *S. Typhi* and *S. Paratyphi* were found to be sensitive to ampicillin, azithromycin, chloramphenicol, ceftriaxone, cotrimoxazole, except ciprofloxacin (9-11%) (Table III). The adjusted incidence of severe typhoid fever was 156.9 per 100,000 PY (95% CI: 127.8-192.4), and severe paratyphoid fever was 69.9 per 1,00,000 PY (95% CI: 51.5-94.95) (Table IV).

The mean OOPE incurred on treatment of study participants infected with *S. Paratyphi* [INR 8696.6 (USD 115.9)] was significantly higher than the study participants having infection with *S. Typhi* [INR 7309 (USD 97.5), *P*=0.01]. The mean OOPE due to hospitalization of adult study participant [INR 8393.6 (USD 111.9)] was significantly higher as compared to the paediatric affected individuals [INR 5481.4 (USD 73.1), *P*<0.001] (Table V).

Discussion

The estimated incidence of 226.8 per 100,000 PY in this investigation was in line with the study conducted by the Global Burden of Disease collaborators in 2017[1]. The reasons for such high incidence in Chandigarh could be the poor hygienic conditions in the study area (urbanized village) leading to higher chances of fecal-oral transmission of the disease; the better health-seeking behavior of the study population and preference to utilize the study hospitals due to their proximity; better detection rates in the blood cultures as these were processed in laboratory at the department of Medical Microbiology, PGIMER, accredited by National Accreditation Board for Testing and Calibration Laboratories (NABL). The culture positivity rate in this study (8.06%) was comparable to the study done by Sharma *et al*[21] in north India (10.8%). The seasonal trend observed in our study was similar to that observed in a time series analysis of the Integrated Disease Surveillance Program's data of the Government of India from 2014 to 2017 in Chandigarh[22].

The higher incidence of typhoid and paratyphoid fever among children (<15 yr), especially school children and males, aligned with the findings of an

Table I. Background characteristics of all febrile illness cases enrolled in the study from May 2018-March 2020 in Chandigarh

Characteristics	EF positive n=133 (%)	EF negative n=1517 (%)	Total AFI N=1650 (%)	P Value
Gender				
Male	85 (63.9)	833 (54.9)	918 (55.6)	0.046
Female	48 (36.01)	684 (45.08)	732 (44.4)	
Age				
Paediatrics (<15 yr)	30 (22.5)	243 (16.01)	273 (16.5)	0.051
Adult (≥15 yr)	103 (77.4)	1274 (83.9)	1377 (83.5)	
Mean age (SD)	21.8 (11.12)	28.4 (15.7)	-	<0·0001
Highest education of any family member in the household				
Illiterate	2 (1.5)	35 (2.3)	37 (2.2)	0.25
Primary	9 (6.8)	116 (7.6)	125 (7.6)	
Middle	29 (21.8)	317 (20.9)	346 (21)	
Secondary	26 (19.5)	255 (16.8)	281 (17)	
Higher secondary	19 (14.3)	344 (22.7)	363 (22)	
Diploma/degree & above	48 (36.1)	450 (29.7)	498 (30.2)	
Highest occupation of any family member in the household				
Business	31 (23.3)	273 (16.5)	304 (18.42)	0.44
Daily wage	31 (23.3)	340 (20.6)	371 (22.4)	
Household work	-	10 (0.6)	10 (0.6)	
Salaried	71 (53.6)	890 (53.9)	961 (58.24)	
Unemployed	-	4 (0.24)	4 (0.2)	
Type of house				
Hut/govt house	-	4 (0.2)	4 (0.2)	0.46
Kutcha		30 (1.9)	30 (1.8)	
Mixed house	-	20 (1.3)	20 (1.2)	
Pucca house	133 (100)	1463 (96.4)	1596 (96.7)	

Association of 6 socio-demographic characteristics with culture confirmation of enteric fever. AFI, all febrile illness; EF, enteric fever; SD, standard deviation; govt, government

earlier study in the region[23] and is possibly linked to eating outside food. The symptoms reported by the study participants were consistent with the clinical features reported by other studies across India[24]. The complications reported in our study were similar but less (5%) than those reported in previous studies[25]. The mean hospitalization (4 days; range up to 2 wk) of enteric fever cases in this study was in line with a previous study[26].

The antimicrobial susceptibility patterns aligned with the patterns reported by other investigators, where *S. Typhi* and *S. Paratyphi* were 100 per cent sensitive to ceftriaxone but resistantto ciprofloxacin[23]. The cause of such resistance against the first line of drugs could be due to overuse of fluoroquinolones over the last decade[27]. The re-emergence of sensitivity to drugs like chloramphenicol might be attributed to the restricted use of chloramphenicol because of the risk of bone marrow suppression.

This study's OOPE estimates exceeded that of the Kolkata study[5] (2004), conducted one and a half decades ago. The Surveillance for Enteric Fever in Asia Project (2016–2018) studies reported a slightly lower OOPE, as they excluded medical costs for non-enteric fever patients[28]. India has one of the world's highest over-the-counter antibiotic sales contributing to growing antibiotic resistance[29] and could lead to higher estimates of out-of-pocket expenditure[30]. A decision analytic modelling study recommended that the use of typhoid conjugate vaccine in the community will reduce mortality and lead to a significant gain in an incremental cost per quality-adjusted life year

Table II. Association of various risk factors with culture confirmed enteric fever cases as per multivariate analysis

Demographics factors	Adjusted OR (95% CI)	*P* value
Sex		
Female	Ref	–
Male	1.4 (1.006, 2.101)	0.046
Age category		
Adult (≥15 yr)	Ref	
Pediatrics (<15 yr)	1.5 (0.99, 2.34)	0.03
Number of days between onset of illness & admission to study hospital		
Same day	0.65 (0.13, 3.04)	0.58
1 day	0.606 (0.2, 1.8)	0.36
2 days	Ref	
≥3 days	2.37 (1.22, 4.604)	0.011
Highest education of any family member in the household		
Illiterate	Ref	
Primary	1.7 (0.42, 7.8)	0.4
Middle	1.3 (0.28, 6.5)	0.7
Secondary	1.6 (0.36, 6.9)	0.53
Higher secondary	0.96 (0.21, 4.3)	0.96
Diploma/degree & above	1.86 (043, 8)	0.4
Highest Occupation of any family member in the household		
Business	Ref	
Daily wage	1.2 (0.72, 2.1)	0.41
Household work	-	
Salaried	1.42 (0.9, 2.2)	0.11
Unemployed	-	

Dependent, enteric fever positive & negative cases; Independent, demographic variables. OR, odds ratio; CI, confidence interval

gained[31].The study by Kumar *et al*[12] (2021) reported the mean cost obtained from all the secondary (tier 2) and tertiary care hospitals (tier 3). We reported Chandigarh-specific estimates as it had the highest culture-confirmed enteric fever cases and represented an urban area (all other sites were rural). However, the total direct and indirect OOPE reported by Kumar *et al*[12] (2021) was higher than that reported in this study because cases were managed in public sector hospitals. In contrast, the study by Kumar *et al*[12] included the cost of 50 per cent of patients being managed at private/charity hospitals with higher OOPE.

The superior sensitivity and specificity of blood culture to that of rapid diagnostic tests like Typhidot IgM led to its preference for detecting bacteremia in this study[32]. As the volume of blood collected is an important predicting factor for getting positive results by blood culture, it is emphasized in this study to detect culture-confirmed typhoid cases[13,14]. If conducted alone, facility-based surveillance would underestimate the disease burden in a community, as not all cases from the catchment would visit that facility. In the hybrid model, the crude incidence rate estimated by facility-based surveillance is adjusted for febrile hospitalizations from the catchment in facilities other than study hospitals[33]. This design represents a strategy for sustainable population-referenced disease burden estimations in low-resource settings like India.

The consecutive recruitment of eligible study participants in the study hospital might be affected by the seasonality, limiting the generalizability of the findings. To address this issue, the surveillance was

Table III. Antimicrobial susceptibility patterns of enteric fever positive blood samples (n=133)

Drug	*Salmonella Typhi* n=92 (%)			*Salmonella Paratyphi* n=41 (%)			Total n=133 (%)			Sensitivity (%)
	S	I	R	S	I	R	S	I	R	
Ampicillin	91 (98.9)	0	1 (1.1)	41 (100)	0	0	132 (99.3)	0	1 (0.7)	99.3
Azithromycin	91 (98.9)	0	1 (1.1)	41 (100)	0	0	132 (99.3)	0	1 (0.7)	99.3
Ceftriaxone	90 (98.9)	0	2 (2.2)	41 (100)	0	0	131 (98.4)	1 (0.7)	0	98.4
Chloramphenicol	91 (98.9)	1 (1.1)	0	41 (100)	0	0	132 (99.3)	1 (0.7)	0	99.3
Ciprofloxacin	9 (9.8)	70 (76.1)	11	6 (11.3)	32	3 (5.7)	15 (11.3)	70	14	11.3
Cotrimoxazole	89 (96.7)	1 (1.1)	2 (2.2)	41 (100)	0	0	130 (97.7)	1 (0.7)	2 (1.4)	97.7
Nalidixic acid	3 (3.3)	2 (2.2)	87 (94.5)	1 (2.4)	2 (4.8)	38 (92.7)	4 (2.8)	2 (1.4)	122 (91.7)	2.8

S, susceptibility; I, intermediate; R, resistant

Age group	Person year	Culture confirm method	Crude incidence	Study facility utilization A1	Compliance to the protocol A2	Blood culture sensitivity A3	Adjusted incidence (Crude Incidence/ A1*A2*A3)	95% CI
Table IV. Incidence of enteric fever per 1,00,000 person-years								
Salmonella Typhi								
Paediatrics (<15 yr)	71,595	21	29.3	0.22	0.88	0.6	252.2	164.68-347.22
Adult (≥15 yr)	1,93,571	71	36.7	0.42	0.99	0.6	147.02	116.52-185.5
Overall	2,65,164	92	34.7	0.38	0.97	0.6	156.9	127.8-192.43
Salmonella Paratyphi								
Paediatrics (<15 yr)	71,595	9	12.6	0.22	0.88	0.6	108.2	55.95-207.98
Adult (≥15 yr)	1,93,571	32	16.5	0.42	0.99	0.6	66.2	46.85-93.71
Overall	2,65,164	41	15.5	0.38	0.97	0.6	69.9	51.5-94.95

Table V. The direct and indirect expenditure on the culture confirmed enteric fever cases enrolled in the study from May 2018-March 2020 in Chandigarh

Characteristics	Enteric fever cases, INR (USD), (n=133)			*P* value
Type	*S. Typhi* (n=92), n(%)	*S. Paratyphi* (n=41), n(%)		
Total family income	20,739 (276.5)	33,244 (443.3)		0.084
Total direct expenditure	4234.5 (56.5)	4475.7 (59.7)		0.245
Total indirect expenditure	3074.5 (41)	4220.9 (56.3)		0.015
Total expenditure	7309 (97.5)	8696.6 (115.9)		0.01
Age group	Paediatric (<15 yr) (n=30)	Adult (≥ 15 yr) (n=103)		
Total direct expenditure	4224.3 (56.3)	4333.5 (57.8)		0.22
Total indirect expenditure	1257.1 (16.8)	4060.2 (54.1)		<0.001
Total expenditure	5481.4 (73.1)	8393.6 (111.9)		<0.001
Gender	Male (n=84)	Female (n=49)		
Total direct expenditure	4127.6 (55)	4619.6 (61.6)		0.32
Total indirect expenditure	4150.8 (55.3)	2188.7 (29.2)		<0.001
Total expenditure	8278.4 (110.4)	6808.2 (90.8)		0.03
Duration of hospitalization	Upto 3 days (n=35)	3-7 days (n=85)	>7 days (n=13)	
Total direct expenditure	2842.5 (37.9)	4704 (62.7)	5672.8 (75.6)	<0.001
Total indirect expenditure	2485.4 (33.1)	3334.2 (44.5)	6578.1 (87.7)	<0.001
Total expenditure	5327.8 (71)	8038.2 (107.2)	12251 (163.3)	<0.001
Outcome of hospitalization	Recovered without complication (n=113)	Sequalae/death/referred) (n=19)		
Total direct expenditure	3952.2 (52.7)	6532.5 (87.1)		<0.001
Total indirect expenditure	3476.7 (46.4)	3141 (41.9)		0.11
Total expenditure	7428.9 (99.1)	9673.5 (129)		<0.001
1USD=75 INR. INR, Indian rupees; USD, US dollar				

extended for more than one year (May 2018 to March 2020), and a hybrid surveillance system was used to estimate the incidence. While the healthcare utilization survey had adjusted this rate, we might have missed some proportion of the population in this age group. The absence of a full-time paediatrician in the study hospitals excluded potential paediatric cases who might not have sought care there. The paediatric patients from

the catchment area enrolled from the referral tertiary care institute might had prior antibiotic consumption, resulting in negative blood culture results. Information on the OOPE on medicines available over the counter was not collected, which might have increased the estimated of OOPE. Although data on water, sanitation and hygiene (WASH) practices were not collected, as the study was conducted primarily in urbanized villages with poor sanitary conditions, the WASH practices were assumed to be compromised.

Overall, this study provided evidence of the high incidence of typhoid disease, OOPE and the emergence of resistance to ciprofloxacin among the population aged six months and above residing mainly in urbanized villages with poor socio-economic, housing, and sanitary conditions in Chandigarh, north India. This evidence might help policymakers implement strategies, such as promoting WASH practices, introducing a typhoid conjugate vaccine, and improving point-of-care diagnostic tests at the primary healthcare level for an early diagnosis of enteric fever. Strengthening existing surveillance systems at the primary, secondary, and tertiary care levels, including the Integrated Disease Surveillance Program (IDSP), is crucial for continuously monitoring typhoid disease incidence and assessing the long-term impact of these interventions.

Conflicts of Interest: None.

Use of Artificial Intelligence (AI)-Assisted Technology for manuscript preparation: The authors confirm that there was no use of AI-assisted technology for assisting in the writing of the manuscript and no images were manipulated using AI.

References

1. Stanaway J, Reiner R, Blacker B, Goldberg E, Khalil I, Troeger C, *et al*. The global burden of typhoid and paratyphoid fevers: A systematic analysis for the global burden of disease study 2017. *Lancet Infect Dis* 2019; *19* : 369-81.

2. John J, Bavdekar A, Rongsen-Chandola T, Dutta S GM, Kanungo S, Sinha B, *et al*. Burden of typhoid and paratyphoid fever in India. *N Engl J Med* 2023; *388* : 1491-500.

3. Lindsay S, Gellin B, Lee A, Garrett D. The coalition against typhoid: Mobilizing a community for a global fight. *Clin Infect Dis* 2019; *68* : S161-4.

4. Andrews JR, Qamar FN, Charles RC, Ryan ET. Extensively drug-resistant typhoid — are conjugate vaccines arriving just in time? *N Engl J Med* 2018; *379* : 1493-5.

5. Poulos C, Riewpaiboon A, Stewart J, Clemens J, Guh S, Agtini M, *et al*. Cost of illness due to typhoid fever in five Asian countries. *Trop Med Int Health* 2011; *16* : 314-23.

6. Institutional Repository for Information Sharing. World Health Organization. *Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring*. Available from: *https://apps.who.int/iris/handle/10665/111548*, accessed on August 23, 2022.

7. World Health Organization. Typhoid vaccines: WHO position paper, March 2018 - Recommendations. *Vaccine* 2019; 37 : 214-16.

8. Dewan D. Community-based typhoid vaccination program in New Delhi, India. In: Eighth International Conference on Typhoid Fever and Other Invasive Salmonelloses; 2013 March 1-2; New Delhi, India.

9. Hoffman SA, LeBoa C, Date K, Haldar P, Harvey P, Shimpi R, *et al*. Programmatic effectiveness of a pediatric typhoid conjugate vaccine campaign in Navi Mumbai, India. *Clin Infect Dis* 2023; *77* : 138-44.

10. John J, Van Aart C, Grassly N. The burden of typhoid and paratyphoid in India: Systematic review and meta-analysis. *PLoS Negl Trop Dis* 2016; *10* : e0004616.

11. Carey M, MacWright W, Im J, Meiring JE, Gibani M, Park S, *et al*. The surveillance for enteric fever in Asia project (SEAP), severe typhoid fever surveillance in Africa (SETA), surveillance of enteric fever in India (SEFI), and strategic typhoid alliance across Africa and Asia (STRATAA) population-based enteric fever studies: A review of methodological similarities and differences. *Clin Infect Dis* 2020; *71* : S102-10.

12. Kumar D, Sharma A, Rana SK, Prinja S, Ramanujam K, Karthikeyan AS, *et al*. Cost of illness due to severe enteric fever in India. *J Infect Dis* 2021; *224* : S540-7.

13. Antillon M, Saad NJ, Baker S, Pollard AJ, Pitzer VE. The relationship between blood sample volume and diagnostic sensitivity of blood culture for typhoid and paratyphoid fever: A systematic review and meta-analysis. *J Infect Dis* 2018; *218* : S255-67.

14. Srinivasan M, Sindhu KN, Ramanujam K, Ramasamy RK, Subramaniam S, Ganesan SK, *et al*. Factors predicting blood culture positivity in children with enteric fever. *J Infect Dis* 2021; *224* : S484-93.

15. BD. BD BACTEC™ FX40 Instrument. Available from: *https:// www.bd.com/en-us/products-and-solutions/products/product-page.442296*, accessed on May 19, 2022.

16. Hudzicki, J. Kirby-Bauer disk diffusion susceptibility test protocol. *Am Soc Microbiol* 2009; *15* : 55-63.

17. Kadhiravan T, Wig N, Kapil A, Kabra SK, Renuka K, Misra A. Clinical outcomes in typhoid fever: Adverse impact of infection with nalidixic acid-resistant Salmonella typhi. *BMC Infect Dis* 2005; *5* : 1-0.

18. Lynch MF, Blanton EM, Bulens S, Polyak C, Vojdani J, Stevenson J, *et al*. Typhoid fever in the United States, 1999-2006. *JAMA* 2009; *302* : 859-65.

19. Raju R, Kezia Angelin J, Karthikeyan A, Kumar D, Kumar R R, Sahai N, *et al*. Healthcare utilization survey in the hybrid model of the Surveillance for Enteric Fever in India (SEFI) study: Processes, monitoring, results, and challenges. *J Infect Dis* 2021; *224* : S529-39.

20. Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale VV, Ramani E, *et al*. Burden of typhoid fever in low-income and middle-income countries: A systematic, literature-based update with risk-factor adjustment. *Lancet Glob Health* 2014; *2* : e570-80.

21. Sharma A, Bala K, Agarwal S, Chaudhary U. Seroprevalence of Salmonella typhi in a tertiary care facility in North India. *Int J Curr Microbiol Appl Sci* 2015; *4* : 946-9.

22. Shashvat K, Basu R, Bhondekar AP, Lamba S, Verma K, Kaur A. Comparison of time series models predicting trends in typhoid cases in Northern India. *Southeast Asian J Trop Med Public Health* 2019; *50* : 347-56.

23. Makkar A, Gupta S, Khan I, Gupta R, Rajmohan K, Chopra H, *et al*. Epidemiological profile and antimicrobial resistance pattern of enteric fever in a tertiary care hospital of North India–A seven year ambispective study. *Acta Medica* 2019; *61* : 125-30.

24. Singh KG, Sundar JS. A study on clinical profile of typhoid fever at Government General Hospital, Nizamabad, Telangana, India. *Int J Contemp Pediatr* 2019; *6* : 2642.

25. Sur D, Barkume C, Mukhopadhyay B, Date K, Ganguly NK, Garrett D. A retrospective review of hospital-based data on enteric fever in India, 2014–2015. *J Infect Dis* 2018; *218* : S206-13.

26. Ahmad MK. A prospective observational evaluation of the clinical and laboratory profiles of typhoid fever in children in the Bihar region of India. *Eur J Mol Clin Med* 2021; *8* : 1377.

27. Sharma P, Dahiya S, Manral N, Kumari B, Kumar S, Pandey S, *et al*. Changing trends of culture-positive typhoid fever and antimicrobial susceptibility in a tertiary care North Indian Hospital over the last decade. *Indian J Med Microbiol* 2018; *36* : 70-6.

28. Mejia N, Abimbola T, Andrews J, Vaidya K, Tamrakar D, Pradhan S, *et al*. Typhoid and paratyphoid cost of illness in Nepal: Patient and health facility costs from the surveillance for enteric fever in Asia project II. *Clin Infect Dis* 2020; *71* : S306-18.

29. Klein EY, Milkowska-Shibata M, Tseng KK, Sharland M, Gandra S, Pulcini C, *et al*. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: An analysis of pharmaceutical sales data. *Lancet Infect Dis* 2021; *21* : 107-15.

30. Selvaraj S, Farooqui HH, Karan A. Quantifying the financial burden of households' out-of-pocket payments on medicines in India: A repeated cross-sectional analysis of National Sample Survey data, 1994–2014. *BMJ Open* 2018; *8* : e018020.

31. Chauhan A, Kapoor I, Rana S, Kumar D, Gupta M, John J, *et al*. Cost effectiveness of typhoid vaccination in India. *Vaccine* 2021; *39* : 4089-98.

32. Mogasale V, Ramani E, Mogasale VV, Park J. What proportion of Salmonella Typhi cases are detected by blood culture? A systematic literature review. *Ann Clin Microbiol Antimicrob* 2016; *15* : 1-8.

33. Andrews J, Barkume C, Yu A, Saha S, Qamar F, Garrett D, *et al*. Integrating facility-based surveillance with healthcare utilization surveys to estimate enteric fever incidence: Methods and challenges. *J Infect Dis* 2018; *218* : S268-76.

For correspondence: Prof Madhu Gupta, Department of Community Medicine and School of Public Health, Post Graduate Institute of
Medical Education & Research, Chandigarh 160 012, India
e-mail: madhugupta21@gmail.com